Physician profile
Rafiq Shahid
NPI 1023422862
$32,651.58
in general payments reported to CMS, 2019-2025
4 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $104 · 2023: $47.76 · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $47.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,500.03 |
| Food and Beverage | $47.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32,500.03 | 2025 | |
| Merck Sharp & Dohme LLC | $103.79 | 2022 | |
| Ge Healthcare | $26.34 | 2023 | |
| Janssen Research & Development, LLC | $21.42 | 2023 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafiq Shahid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.